Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
Catalog No. | Product Name | Size | List Price (US$) | Quantity |
---|
The manufacturing conditions of BeneFIX biosimilar from the CHO stable cell line need to be optimized by clients.
Syd Labs does not sell BeneFIX biosimilar as a drug in any country or area.
Price/availability/specifications subject to change without notice. Unless otherwise indicated, our catalog and customized products are for research use only and not intended for human or animal diagnostic or therapeutic use.
Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
BeneFIX, recombinant factor IX, is used to treat hemophilia B. Lack of Factor IX (Christmas factor), one of the serine proteases of the coagulation system, causes hemophilia B, a recessive X-linked genetic disorder and about 20% of haemophilia cases.
C019: BeneFIX Biosimilar Stable Cell Line (CHO)
The yield of BeneFIX biosimilar from the CHO stable cell line was above 20 IU/mL in a 15 liter manufacturing.
The BeneFIX biosimilar stable cell line alone can be transferred alone or together with the technology of process development and/or antibody purification.
Syd Labs also provides the following clotting or coagulation-related biosimilar stable cell lines:
Advate / Kogenate Biosimilar Stable Cell Line (Factor VIII)
ReFacto Biosimilar Stable Cell Line (truncated Factor VIII)
NovoSeven Biosimilar Stable Cell Line (Factor VIIa)
Copyright © 2009-2022 sydlabs.com. All rights reserved.
Use of this website means that you have read, understood, and accepted the Syd Labs Privacy Policy and Terms & Conditions.